# Lekang Jiarun

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lekang-jiarun

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Latest round: Angel (May 22, 2024)
- Investors on record: 2

## About

Founded in 2022 and based in Hangzhou, China, Lekang Jiarun is a biotech company that focuses on the research and development of anti-tumor drugs. In May 2024, the firm closed an angel funding. Dawei Chen, the company’s chief scientist, founded Baiintaihe and served as the dean of the School of Pharmacy at Shenyang Pharmaceutical University.
The company has anti-tumor platinum prodrug technology platform, nucleic acid drug delivery system technology platform, hypoglycemic peptide non-injection drug delivery technology platform and other drug research and development platforms. Its main products include divalent platinum drugs and quadrivalent platinum prodrugs. The company also provides CRO business services and generic drug research and development services.
The company’s revenue is generated by providing anti-tumor drugs.
The company will use the angel funding for innovative drug research and development to enhance its team and market expansion capabilities.

## Funding rounds

- Angel, May 22, 2024 — Miaoshou Doctor/Beijing Youyiku Technology Co.,Ltd., Anhui Xiangchuan Private Equity Fund Management

## Investors

- Miaoshou Doctor/Beijing Youyiku Technology Co.,Ltd. — Angel
- Anhui Xiangchuan Private Equity Fund Management (https://capitalatlas.ai/funds/anhui-xiangchuan-private-equity-fund-management) — Angel